Allena Pharmaceuticals, Inc. (ALNA)
(Delayed Data from NSDQ)
$6.30 USD
+0.20 (3.28%)
Updated May 3, 2019 04:00 PM ET
After-Market: $6.30 (%) 5:22 PM ET
NA Value NA Growth NA Momentum NA VGM
View All Zacks #1 Ranked Stocks
Brokerage Reports
Allena Pharmaceuticals, Inc. [ALNA]
Reports for Purchase
Showing records 1 - 20 ( 170 total )
Company: Allena Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Price: 5.00
Company: Allena Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q22 Results; Focus on ALLN-346 and Raising Capital
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Price: 12.50
Company: Allena Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
4Q21 Results; Focusing On ALLN-346 Studies With Top-Line Data Expected in 2Q22
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Price: 12.50
Company: Allena Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Price: 5.00
Company: Allena Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Price: 12.50
Company: Allena Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Price: 25.00
Company: Allena Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Happy New Year''s with Positive ALLN-346 Phase 2a Cohort A Data
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Price: 12.50
Company: Allena Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
KOL Call Held to Discuss Positive ALLN-346 Data; Reloxaliase Program Update Provided
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Price: 12.50
Company: Allena Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Price: 12.50
Company: Allena Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q3: ALLN-346''s Life in the Fast (Track Designation) Lane;URIROX-2 Rolls Along
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Price: 12.50
Company: Allena Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q21 Results; Plethora of Data Expected in 1Q22
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Price: 12.50
Company: Allena Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
FDA Grants Fast Track Designation for ALLN-346 for Hyperuricemia in Patients With Gout and Advanced CKD
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Price: 5.00
Company: Allena Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
ALLN-346 Dosing Initiated in Gout Patients in Phase 2a Trial (Study 202)
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Price: 10.00
Company: Allena Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Price: 25.00
Company: Allena Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Price: 25.00
Company: Allena Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q2: Bolstered Balance Sheet Covers Multiple Value-Driving Clinical Readouts
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Price: 25.00
Company: Allena Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q21 Results; Continuing to Move the Ball Down the Field; Raise PT to $11 From $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Price: 25.00
Company: Allena Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Major Catalysts Move Closer; URIROX-2 Interim Now in Q1:22, ''346 Ph2 in Q4:21
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Price: 25.00
Company: Allena Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
A Nice Surprise, Timing of Interim Phase 3 Data Moves Up
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Price: 10.00
Company: Allena Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Price: 25.00